ArticleFrontiers in medicine2023

Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome.

Simon Bossart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.